Search

Your search keyword '"Katsanos, Andreas"' showing total 472 results
Start Over Author "Katsanos, Andreas"
472 results on '"Katsanos, Andreas"'

3. Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study

Author

Rulli, Eliana, Quaranta, Luciano, Riva, Ivano, Poli, Davide, Hollander, Lital, Galli, Fabio, Katsanos, Andreas, Oddone, Francesco, Torri, Valter, and Weinreb, Robert N

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Eye, Italian Study Group on QoL in Glaucoma
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

4. Author Correction: Vision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patients.

Author

Riva, Ivano, Legramandi, Lorenzo, Rulli, Eliana, Konstas, Anastasios G, Katsanos, Andreas, Oddone, Francesco, Weinreb, Robert N, Quaranta, Luciano, and Italian Study Group on QoL in Glaucoma*

Subjects
Italian Study Group on QoL in Glaucoma*
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

7. Vision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patients.

Author

Riva, Ivano, Legramandi, Lorenzo, Rulli, Eliana, Konstas, Anastasios G, Katsanos, Andreas, Oddone, Francesco, Weinreb, Robert N, Quaranta, Luciano, and Italian Study Group on QoL in Glaucoma

Subjects
Italian Study Group on QoL in Glaucoma
Abstract

To evaluate the change over time of vision-related quality of life (QoL) and glaucoma symptoms in a population of newly-diagnosed primary open angle glaucoma (POAG) patients. Multicenter, prospective study. Consecutive newly-diagnosed POAG patients were enrolled and followed-up for one year. Follow-up visits were scheduled at 6 and 12 months from baseline. At each visit, vision-related QoL and glaucoma-related symptoms were assessed by the means of the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and the Glaucoma Symptom Scale (GSS), respectively. Trends over time for NEI-VFQ-25 and GSS scores were evaluated with longitudinal linear mixed models. One-hundred seventy-eight patients were included in the analysis. At baseline, early to moderate glaucoma stages were associated with higher scores for most GSS and NEI-VFQ-25 items, while lower best-corrected visual acuity was associated with lower scores for 4 of the 12 NEI-VFQ-25 items. During the follow-up, all the GSS scores, the NEI-VFQ-25 total score, and 7 of the 12 NEI-VFQ-25 scores significantly improved (p

Published
2019

11. Ocular Rigidity and Drugs

Author

Katsanos, Andreas, Dastiridou, Anna I., Konstas, Anastasios G. P., Pallikaris, Ioannis, editor, Tsilimbaris, Miltiadis K., editor, and Dastiridou, Anna I., editor

Published
2021
Full Text
View/download PDF

13. OCT Angiography of the Retina and the Choroid in the Macula in Patients with Normal Tension Glaucoma and Primary Open Angle Glaucoma.

Author

Dastiridou, Anna, Samouilidou, Maria, Anastasopoulos, Eleftherios, Koronis, Spyridon, Riga, Paraskevi, Katsanos, Andreas, Ziakas, Nikolaos, and Androudi, Sofia

Subjects
OPEN-angle glaucoma, MACULA lutea, NERVE fibers, BLOOD flow, GLAUCOMA
Abstract

The aim of this study was to compare vessel density (VD) in the retina and choroid in eyes with primary open angle glaucoma (POAG), normal tension glaucoma (NTG) and controls. Patients with POAG, NTG and controls underwent OCT scanning of the macula and the disc followed by 6 × 6 mm macula OCT angiography (OCTA) imaging. Global and hemifield VD were recorded for the superficial (SVP) and deep (DVP) vascular plexus and the choriocapillaris (CC). The OCT thickness of the nerve fiber layer (NFL) and ganglion cell layer (GCC) was also measured. Data from 65 POAG, 33 NTG and 40 control eyes matched for age were analyzed. Mean SVP VD was lower in NTG and POAG eyes compared to controls (38.8 ± 5.3, 40.7 ± 6.8 and 48.5 ± 4.0%, p < 0.001). Mean DVP VD was lower in NTG and POAG eyes compared to controls (43.1 ± 6.1, 44.5 ± 7.6 and 48.6 ± 5.8%, p = 0.002). There was no difference in SVP VD or DVP VD between the glaucoma groups (p > 0.050). No difference was noted in CC VD between the groups (68.3 ± 2.3, 67.6 ± 3.7 and 68.5 ± 2.6%, p = 0.287). Lower SVP and DVP VD was seen in eyes with glaucoma compared to normal eyes. NTG and POAG eyes had similar VD loss. Eyes with glaucoma manifested similar CC VD compared to controls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study.

Author

Rulli, Eliana, Quaranta, Luciano, Riva, Ivano, Poli, Davide, Hollander, Lital, Galli, Fabio, Katsanos, Andreas, Oddone, Francesco, Torri, Valter, Weinreb, Robert N, and Italian Study Group on QoL in Glaucoma

Subjects
Italian Study Group on QoL in Glaucoma, Humans, Vision Disorders, Glaucoma, Open-Angle, Quality of Life, Adult, Aged, Aged, 80 and over, Middle Aged, Italy, Female, Male, Young Adult, Visual Field Tests, Surveys and Questionnaires, and over, Glaucoma, Open-Angle
Abstract

The aim of this study was to examine the relationship between visual field (VF) loss, vision-related quality of life (QoL) and glaucoma-related symptoms in a large cohort of primary open angle glaucoma (POAG) patients. POAG patients with or without VF defects or "glaucoma suspect" patients were considered eligible. QoL was assessed using the validated versions of the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and glaucoma-related symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were classified as having VF damage in one eye (VFD-1), both eyes (VFD-2), or neither eye (VFD-0). 3227 patients were enrolled and 2940 were eligible for the analysis. 13.4% of patients were classified in the VFD-0, 23.7% in the VFD-1, and 62.9% in the VFD-2 group. GSS visual symptoms domain (Func-4) and GSS non-visual symptoms domain (Symp-6) scores were similar for the VFD-0 and VFD-1 groups (p = 0.133 and p = 0.834 for Func-4 and Symp-6, respectively). VFD-0 group had higher scores than VFD-2 both in Func-4 (p

Published
2018

20. Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics

Author

Quaranta, Luciano, Biagioli, Elena, Galli, Francesca, Poli, Davide, Rulli, Eliana, Riva, Ivano, Hollander, Lital, Katsanos, Andreas, Longo, Antonio, Uva, Maurizio G, Torri, Valter, and Weinreb, Robert N

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Clinical Research, Neurosciences, Pediatric, Clinical Trials and Supportive Activities, Aging, Neurodegenerative, Eye Disease and Disorders of Vision, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Antihypertensive Agents, Child, Child, Preschool, Drug Therapy, Combination, Female, Glaucoma, Humans, Infant, Intraocular Pressure, Italy, Latanoprost, Male, Prospective Studies, Prostaglandins F, Synthetic, Sulfonamides, Thiophenes, Treatment Outcome, Dorzolamide, Medical therapy, Ophthalmology, Pediatric glaucoma, Surgery, Pharmacology and Pharmaceutical Sciences, General Clinical Medicine, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

IntroductionTo investigate the efficacy of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery.MethodsSingle arm, prospective, interventional multicenter study. Primary pediatric glaucoma patients younger than 13 years after a single surgical procedure with IOP between 22 and 26 mmHg were considered eligible. At baseline, patients were allocated to latanoprost monotherapy once daily. Depending on intraocular pressure (IOP) reduction at first visit, the patients were allocated to one of three groups: continuation of latanoprost monotherapy, addition of dorzolamide twice daily, or switch to dorzolamide three times daily. The same approach for allocation in medication groups was used in all subsequent visits. Patients in the dorzolamide monotherapy group with IOP reduction

Published
2016

40. Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

Author

Konstas, Anastasios-Georgios, Boboridis, Konstadinos G., Kapis, Paraskevas, Marinopoulos, Konstantinos, Voudouragkaki, Irini C., Panayiotou, Dimitrios, Mikropoulos, Dimitrios G., Pagkalidou, Eirini, Haidich, Anna-Bettina, Katsanos, Andreas, and Quaranta, Luciano

Published
2020
Full Text
View/download PDF

45. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

Author

Konstas, Anastasios-Georgios, Boboridis, Konstadinos G., Kapis, Paraskevas, Marinopoulos, Konstantinos, Voudouragkaki, Irini C., Panayiotou, Dimitrios, Mikropoulos, Dimitrios G., Pagkalidou, Eirini, Haidich, Anna-Bettina, Katsanos, Andreas, and Quaranta, Luciano

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results